Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Financing Activities: 2023-2024

Historic Cash from Financing Activities for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $628.3 million.

  • CG Oncology's Cash from Financing Activities rose 2409.00% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.9 million, marking a year-over-year decrease of 30.86%. This contributed to the annual value of $628.3 million for FY2024, which is 622.18% up from last year.
  • Latest data reveals that CG Oncology reported Cash from Financing Activities of $628.3 million as of FY2024, which was up 622.18% from $87.0 million recorded in FY2023.
  • CG Oncology's Cash from Financing Activities' 5-year high stood at $628.3 million during FY2024, with a 5-year trough of $87.0 million in FY2023.
  • Moreover, its 2-year median value for Cash from Financing Activities was $357.6 million (2023), whereas its average is $357.6 million.
  • Data for CG Oncology's Cash from Financing Activities shows a peak YoY surged of 622.18% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows CG Oncology's Cash from Financing Activities stood at $87.0 million in 2023, then spiked by 622.18% to $628.3 million in 2024.